enGene (NASDAQ:ENGN) Stock Price Up 5.9%

enGene Holdings Inc. (NASDAQ:ENGN)’s share price shot up 5.9% during mid-day trading on Friday . The company traded as high as $15.00 and last traded at $15.00. 5,384 shares were traded during trading, a decline of 88% from the average session volume of 43,121 shares. The stock had previously closed at $14.17.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ENGN shares. Morgan Stanley began coverage on shares of enGene in a research report on Friday, March 8th. They set an “overweight” rating and a $40.00 price target for the company. UBS Group started coverage on shares of enGene in a research note on Thursday, March 28th. They set a “buy” rating and a $37.00 price target on the stock. SVB Leerink began coverage on enGene in a report on Tuesday, February 20th. They issued an “outperform” rating and a $31.00 target price on the stock. Guggenheim began coverage on enGene in a report on Monday. They set a “buy” rating and a $34.00 price target for the company. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of enGene in a research note on Tuesday, February 20th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $35.50.

enGene Trading Up 4.1 %

The firm’s 50-day simple moving average is $15.83.

Institutional Investors Weigh In On enGene

A number of institutional investors and hedge funds have recently bought and sold shares of ENGN. Citadel Advisors LLC bought a new position in shares of enGene in the fourth quarter worth about $185,000. Goldman Sachs Group Inc. purchased a new position in enGene in the 4th quarter worth approximately $346,000. Royal Bank of Canada bought a new position in enGene in the 4th quarter worth approximately $349,000. Vivo Capital LLC purchased a new stake in enGene during the 4th quarter valued at approximately $6,264,000. Finally, Omega Fund Management LLC bought a new stake in shares of enGene during the fourth quarter valued at approximately $10,441,000. 64.16% of the stock is owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.